


making financial sense of the future

## Open Forum 16 September 2010, Staple Inn Kamran Foroughi




## Solvency II FD: "economic risk-based approach ... so companies properly measure/manage risks"



Amount exchanged/transferred between knowledgeable willing parties

## IASB Phase II Insurance Contracts: "provide relevant information to users for economic decision-making"



Consistent with current observable market prices

## **Advantages of MCV**

- Easier value comparison
- More objective
- Better consistency
- Link with ALM and risk management

#### Some commercial challenges

- Increased volatility
- 2. Procyclicality and other macroeconomic effects
- 3. How to price in certain markets?
- 4. Where is the capital information?

## A wider reporting pack

Balance sheet, earnings, new business impact and sensitivities		
Solvency II regulatory reporting	IFRS	MCEV / MCV


Cash flow and capital			
Distributable earnings (RW)	Implied MCV Discount Rate	Net fund flows	

New business metrics			
Volumes	Initial Strain	Internal Rate of Return	Payback period

## Revisiting technical issues

- Allowance for risk approach
- How to value financial instruments in illiquid markets?
- Selecting a reference rate ("risk-free" rate)
- Liquidity premium adjustments?
- Calibrating stochastic models
- Allowance for Non-Hedgeable Risk
- Allowance for own credit risk?
- Valuation of other assets and liabilities.

#### Overall allowance for risk



#### Key issues:

- "Assets and liabilities separately" or "Blocks of business"?
- Transfer value / Going concern value?
- Which market to calibrate to?

### **Asset valuation developments**

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an <u>orderly transaction</u> between <u>market participants</u> at the measurement date


Source: Fair Value Measurement Exposure Draft, IASB May 2009

#### Key issues:

- Orderly transaction
- Mark-to-model
- Bid or mid price?

# Candidates for the reference rate (pre-liquidity premium)

**UK GBP: Zero Coupon Yields** 




Source: Towers Watson analysis of Bloomberg data

#### Reference rate: key issues

- "Risk-free" rate plus liquidity premium
  - Trend within MCEV, Solvency II and IFRS Phase II
- 100%-credit-risk-free versus suitably low credit risk matching asset
  - Theory versus practice
- Swaps versus government bonds versus high quality corporate yield
  - Solvency II and MCEV trend towards swaps
  - Eurozone issues with government bonds
  - Accounting mismatch issues with corporate debt
- How to calibrate the corporate bond liquidity premium?
  - Residual spread approach
  - Solvency II QIS 5 formula: "50% \* (corp. bond yield swap yield 40bp)"
- How much liquidity premium in the valuation?

## Level of liquidity risk premium in illiquid assets

Eurozone and USD illustrative residual spreads (average up to 10 years) and draft QIS5 liquidity premium relative to swaps



Sources: Towers Watson analysis of Bloomberg and Markit data; April 2010 draft QIS5 technical specification including CFO Forum/CRO Forum paper on risk-free rates

### Liquidity premium in the valuation: key issues

- Liability-only restrictions
  - "LP should be independent of the investment strategy adopted by company" (Task force report LP principle 2)
  - Efficient market hypothesis in an illiquid and inefficient market?
- Liability, assets and ALM strategy restrictions
  - What viable investment strategies are available to insurer?
  - "LP ...should not exceed extra return which can be earned by insurer holding illiquid assets free of credit risk, available in the financial markets and matching the cash flows of the liability" (Task force report LP principle 3, CFO/CRO Forum paper)

### Valuation of embedded financial options

"Implied volatility is the wrong parameter in the wrong model to get the right price"

#### Adjustments to option market prices

#### My preferred reasons

- Disorderly option markets
  - Valuation of option assets?
- Non-existent option markets
  - Fair value principles
- Liquidity premium only for nonoption sub-block

#### Other reasons

- Remove credit risk within market prices
- ESG cannot handle high prices
- Prices much higher than last year
- Historic volatilities "better"

## Risk adjustment/margin

	Solvency II	IASB Phase II
Purpose	To ensure that the value of the technical provisions is equivalent to the amount insurers would be expected to require in order to take over and meet their obligations	The maximum amount the insurer would rationally pay to be relieved of the risk that the ultimate fulfilment cash flows exceed those expected
Measurement	Cost of capital	Cost of capital, or
technique		Confidence level, or
		Conditional tail expectation
		(Confidence level has to be disclosed)
Cost of capital	QIS 5: 6% p.a.	Not prescribed
	CEIOPS: At least 6% p.a.	
Diversification	QIS 5: Yes	No
allowed between portfolios	CEIOPS: Potentially not	

### Allowance for NHR – recommended process

Consider Asymmetric Non-Interallowance for **Definition of** Risks not impact hedgeable dependencies NHR best estimates included on value financial risk uncertainty

Can be used across reporting measures

#### Allowance for own credit risk

"value assets and liabilities as follows:

- (a) assets....
- (b) liabilities shall be valued at the amount for which they could be transferred, or settled, between knowledgeable willing parties in an arm's length transaction When valuing liabilities under point (b), no adjustment to take account of the own credit standing of the insurance or reinsurance undertaking shall be made."

Source: Framework Directive Article 75 Valuation of assets and liabilities (extract)

QIS 5 specification: "subsequent"

#### Valuation of other assets and liabilities

	IASB	Solvency II QIS 5
Corporate debt	IAS 39 Financial Instruments Typically amortised cost or fair value	Entry value updated for new risk- free rate
Pension Scheme valuation	IAS 19 Employee Benefits	Follow IAS 19
Valuation of tax assets and liabilities	IAS 12 Income Taxes	Follow IAS 12

#### **Preferred valuation metric?**

Traditional non-MCV

2. MCV developed pre-financial crisis

3. MCV revised post-financial crisis

Different metrics encourage different behaviours